Eye Diseases, Hereditary: Clinical Trials

1,165 trials for Eye Diseases, Hereditary, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

524 completed, 199 recruiting, 151 unknown, 95 active not recruiting. 288 Phase 2, 248 Not applicable, 217 Phase 1, 135 Phase 3, 49 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 2288Completed 115, Recruiting 39, Terminated 38, Active not recruiting 37, Unknown 36, Withdrawn 11, Not yet recruiting 8, Enrolling by invitation 3, Suspended 1
Not applicable248Completed 123, Unknown 47, Recruiting 27, Active not recruiting 13, Terminated 12, Withdrawn 12, Not yet recruiting 8, Enrolling by invitation 6
Phase 1217Completed 99, Recruiting 38, Active not recruiting 29, Terminated 20, Unknown 19, Not yet recruiting 7, Withdrawn 3, Enrolling by invitation 2
Phase 3135Completed 54, Recruiting 20, Active not recruiting 19, Terminated 17, Unknown 12, Not yet recruiting 8, Withdrawn 5
Phase 449Completed 23, Recruiting 9, Unknown 8, Not yet recruiting 4, Terminated 2, Withdrawn 2, Active not recruiting 1
Early Phase 126Recruiting 9, Unknown 6, Completed 4, Not yet recruiting 3, Active not recruiting 2, Suspended 1, Terminated 1

Follow Eye Diseases, Hereditary: new trials by email Literature Review of Eye Diseases, Hereditary trials Research Report on Eye Diseases, Hereditary

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Open-Label Extension Study of MHB018A in Patients With Thyroid Eye Disease
MHB018A injection - Thyroid Eye Disease (TED)
Phase 3Not yet recruitingMinghui Pharmaceutical (Hangzhou) Ltd2192027-07-012026-06-04
Non-invasive Ultrasound Retinal Stimulation for Vision Restoration
Non-invasive ultrasound retinal stimulation Device - Age-Related Macular Degeneration, Retinitis Pigmentosa
Not applicableNot yet recruitingUniversity of Southern California52027-01-102026-01-08
24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
N-acetylcysteine amide, Placebo - Retinitis Pigmentosa (RP), Usher Syndrome
Phase 3Not yet recruitingNacuity Pharmaceuticals, Inc.802026-12-012026-07-01
A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participants
CITY-RBP4, Placebo - Stargardt Disease 1, STGD1
Phase 1RecruitingCity Therapeutics482026-11-042026-11-12
Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department
Haloperidol - Cannabinoid Hyperemesis Syndrome
Early Phase 1Not yet recruitingUniversity of Illinois at Chicago1002026-11-012026-09-01
Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO)
Atorvastatin - Graves Disease, Graves Disease (Basedow's Disease)
Phase 2Not yet recruitingRegion Skane5542026-11-012026-10-20
Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment
Active hf-tRNS., Placebo/sham hf-tRNS - Retinitis Pigmentosa (RP), Rod Cone Dystrophy
Not applicableRecruitingUniversity of Waterloo202026-11-012026-11-03
A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
Placebo, NPI-001 - Retinitis Pigmentosa (RP), Usher Syndrome
Phase 3RecruitingNacuity Pharmaceuticals, Inc.802026-10-232026-11-10
Early Risk Stratification of Thyroid Eye Disease in Newly Diagnosed Graves' Disease
Study-related ophthalmological assessment and biospecimen collection, Blood biomarkers and standardized blood samples including thyroid function status - Graves' Orbitopathy, Thyroid Eye Disease, TED
RecruitingUniversity of Copenhagen4302026-10-162026-10-27
Transconjunctival Versus Transcutaneous Betamethasone for Upper Eyelid Retraction in TED
Betamethasone - Thyroid Eye Disease
Not applicableNot yet recruitingAssiut University542026-10-102026-10-08
Study to Evaluate the Long-Term Safety of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
No intervention, will not receive any active study intervention, Intravitreal Injection of Ultevursen - Retinitis Pigmentosa (RP), Usher Syndrome Type 2
Phase 2Not yet recruitingLaboratoires Thea812026-10-052026-09-01
Retinal and Choroidal Changes in Periodontal Disease
Periodontal Diseases, Periodontal Diseases Inflammation
Not yet recruitingZeliha Başak Çakır Erdil802026-10-012026-10-05
Partial Range Of Field IOLs in DMEK-Enabled Procedures
combined cataract and lamellar endothelial keratoplasty - Cataract, Fuchs Endothelial Corneal Dystrophy
Not applicableNot yet recruitingUniversitair Ziekenhuis Brussel102026-10-012026-08-25
Safety and Efficacy Study of GEB-101 Injection in Subjects With TGFBI-related Corneal Dystrophy
GEB-101 Injection - Hereditary Corneal Dystrophy, Corneal Abnormality
Phase 1 / Phase 2Not yet recruitingGenEditBio Limited302026-10-012026-09-10
Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction
150K cells, 500K cells, Placebo - Corneal Edema, Fuchs
Phase 2RecruitingEmmecell1212026-10-012026-10-09
Safety Evaluation Study of Pitavastatin PLGA Nano-particle for Retinitis Pigmentosa
ULREA-PVS-NP - Retinitis Pigmentosa (RP)
Phase 1RecruitingKyushu University212026-10-012026-10-07
Study to Evaluate the Efficacy of a Single Intravitreal Injection of RTx-015 in Participants With Retinitis Pigmentosa (PERCEPT)
RTx-015, Sham Control - Retinitis Pigmentosa (RP), Inherited Retinal Diseases
Phase 2 / Phase 3RecruitingRay Therapeutics, Inc.602026-10-012026-10-28
Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA-Associated Inherited Retinal Degeneration (LCA-IRD)
OPGx-RDH12 - Leber Congenital Amaurosis, Leber Congenital Amaurosis (LCA)
Phase 1 / Phase 2RecruitingOpus Genetics, Inc102026-10-012026-10-30
Phase I/II Open-Label Trial of UGX202 for Advanced Retinitis Pigmentosa
UGX202 Injection - Retinitis Pigmentosa (RP)
Phase 1Not yet recruitingSuzhou UgeneX Therapeutics Co., Ltd.122026-09-282026-10-02
Treatment of Active Thyroid Eye Disease With MHB018A in a Randomized, Placebo-Controlled Study
MHB018A, MHB018A placebo - Thyroid Eye Disease, TED
Phase 3RecruitingMinghui Pharmaceutical (Hangzhou) Ltd842026-09-282026-10-14

Showing 20 of 1165. Sign in to see all of them.

Narrower conditions

Retinitis Pigmentosa (268)  ·  Graves Ophthalmopathy (197)  ·  Retinal Degeneration (130)  ·  Retinoblastoma (117)  ·  Eye Diseases (100)  ·  Retinal Diseases (96)  ·  Fuchs' Endothelial Dystrophy (92)  ·  Macular Degeneration (86)  ·  Stargardt Disease (66)  ·  Color Vision Defects (62)  ·  Optic Atrophy, Hereditary, Leber (44)  ·  Vision Disorders (40)  ·  Cone-Rod Dystrophies (39)  ·  Graves Disease (36)

Broader conditions

Eye Diseases (1048)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (917)  ·  Genetic Diseases, Inborn (888)  ·  Retinal Diseases (491)  ·  Retinal Degeneration (313)  ·  Nervous System Diseases (298)  ·  Retinal Dystrophies (274)  ·  Endocrine System Diseases (253)  ·  Pathological Conditions, Signs and Symptoms (248)  ·  Immune System Diseases (236)  ·  Autoimmune Diseases (202)  ·  Goiter (195)  ·  Orbital Diseases (193)  ·  Signs and Symptoms (192)

Interventions

Carboplatin (26)  ·  Etoposide (24)  ·  Methylprednisolone (23)  ·  Melphalan (18)  ·  Vincristine (18)  ·  Filgrastim (15)  ·  aflibercept (15)  ·  teprotumumab (15)  ·  salicylhydroxamic acid (14)  ·  Cyclophosphamide (13)  ·  Topotecan (11)  ·  Granulocyte Colony-Stimulating Factor (10)  ·  Blood Specimen Collection (9)  ·  Ophthalmic Solutions (9)  ·  Ranibizumab (9)

Sponsors

National Eye Institute (NEI) (34)  ·  Sun Yat-sen University (26)  ·  Amgen (16)  ·  Johns Hopkins University (16)  ·  Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts (13)  ·  Beacon Therapeutics (11)  ·  University of Pisa (11)  ·  Memorial Sloan Kettering Cancer Center (10)  ·  St. Jude Children's Research Hospital (10)  ·  GenSight Biologics (9)  ·  National Human Genome Research Institute (NHGRI) (9)  ·  Viridian Therapeutics, Inc. (9)  ·  Columbia University (8)  ·  Laboratoires Thea (8)  ·  MeiraGTx UK II Ltd (8)

Countries

United States (539)  ·  France (143)  ·  Germany (119)  ·  United Kingdom (118)  ·  China (110)  ·  Canada (73)  ·  Italy (70)  ·  Spain (60)  ·  Netherlands (54)  ·  Australia (48)  ·  Poland (32)  ·  Israel (30)  ·  Belgium (28)  ·  Brazil (27)  ·  Denmark (23)

Top investigators

Brian P Brooks, M.D. (8)  ·  Pablo Velazquez-Martin, MD (7)  ·  Francis W Price, Jr, MD (5)  ·  Carlos Rodriguez-Galindo, MD (4)  ·  Dan Liang (4)  ·  Dan Liang, MD (4)  ·  David Meeker, MD (4)  ·  Jennifer Henrick, RN, MS (4)  ·  Mohamed Genead, MD (4)  ·  Umut Arslan, MD (4)

Results publications

PMID 30194931, PMID 32573764, PMID 40547876, PMID 36449262, PMID 34108929, PMID 23049090, PMID 37261916, PMID 37314061, PMID 38254722, PMID 17102659, PMID 18441370, PMID 18441371, PMID 18774912, PMID 19953081, PMID 21606598, PMID 22281388, PMID 22323828, PMID 22562517, PMID 22761263, PMID 23668681, PMID 24150759, PMID 25458728, PMID 25812924, PMID 26199618, PMID 26604914, PMID 26606867, PMID 26892229, PMID 27857759, PMID 27904503, PMID 28878616, PMID 29445374, PMID 29940167, PMID 30369044, PMID 31215818, PMID 31401903, PMID 32131056, PMID 32303913, PMID 32343050, PMID 32787913, PMID 33591032, PMID 33768488, PMID 34633355, PMID 35814763, PMID 39207600, PMID 41066062, PMID 41126474, PMID 10511047, PMID 10548467, PMID 10634372, PMID 10656302

NIH funding

2017 (11), 2016 (7), 2018 (7), 2023 (7), 2015 (6), 2009 (3), 2019 (3), 2025 (3), U10CA098543 (3), 2014 (2), P01CA023099 (2), P30CA008748 (2), P30CA021765 (2), R24EY022023 (2), 1UG1EY030030-01A1 (1)